Zentalis Pharmaceuticals
Market cap $146M 98.3M shares (10-Q, Nov 4, 2026) × $1.49 close Nov 17, 2026
Most recent annual filing: 2026-03-26
- Azenosertib corporate updateby year-end 2026Azenosertib corporate update, by year-end 2026, notable
- Azenosertib China decisionDec 2026Azenosertib China decision, Dec 2026, material
- Azenosertib topline1H 2027Azenosertib topline, 1H 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Discontinued (2)
- azenosertib — Uterine Serous Carcinoma · We do not plan further development of azenosertib in USC.
- azenosertib — Colorectal Cancer · resource prioritization and evolving treatment landscape; did not advance to dose expansion
Capital (as filed)
- Cash
- $24.0M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $205M Sep 30, 2026
- Operating cash flow
- −$32.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $229M cash, runway first half of 2028 per the update of Nov 9, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (3)
- 2026-11-10 UPDATE: Zentalis Pharmaceuticals (ZNTL) - The Trigger Fires, The Pathway Wobbles ★ Distilled Pro
- 2026-10-20 UPDATE: Zentalis Pharmaceuticals (ZNTL) - The Survival Number Arrives ★ Distilled Pro
- 2026-08-21 Zentalis Pharmaceuticals (ZNTL) - Scientific Deep Dive for Azenosertib and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (3 calls)
Every verdict Biotech Distilled has published on Zentalis Pharmaceuticals, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-08-21 Speculative buy speculative Zentalis Pharmaceuticals (ZNTL) - Scientific Deep Dive for Azenosertib and Pipeline Products Mechanism replicates across three independent studies and the August raise fully funds the 1H 2027 binary, but pivotal efficacy has never been shown and the approved competitive bar moved in March 2026.
- 2026-10-20 Speculative buy speculative UPDATE: Zentalis Pharmaceuticals (ZNTL) - The Survival Number Arrives First OS read directionally answers the sharpest bear point and enterprise value is near zero, but data is interim, retrospective, single-arm, and the named add trigger (Part 2c enrollment re-guidance) has not yet fired.
- 2026-11-10 Buy core UPDATE: Zentalis Pharmaceuticals (ZNTL) - The Trigger Fires, The Pathway Wobbles The named add trigger fired (Part 2c enrollment completes November 2026), enterprise value is negative on $228.9M cash with runway into 1H 2028, and mature OS data held up, warranting moving toward full intended size within the 1–2% cap.
- Long call · opened Aug 21, 2026 at $3.83 · -61.0% vs XBI -12.3% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Although we do not currently anticipate that supply of azenosertib will be affected by the implementation of the BIOSECURE Act, the impact of the BIOSECURE Act or any related legislation remains uncertain, and we are continuing to monitor regulatory developments including the publication of the list of designated biotechnology companies of concern expected by December 2026 and subsequent implementing guidance.”
matched to Azenosertib (China-based drug substance) · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (24)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 9, 2026ReleaseZentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates→ BD updateSummary on the 8-K
- Nov 9, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD updateZNTL's Q3 10-Q confirms $228.9M cash (runway into 1H 2028), Part 2c enrollment completing this month — the trigger I named as the "add" signal — but the company's new language on accelerated approval reveals a meaningful regulatory hedge that investors should not miss.
- Nov 9, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 23, 2026ReleaseZentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
- Oct 18, 2026ReleaseZentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract→ BD updateDENALI Part 1b posts the first-ever OS data for azenosertib: 15.8 months median in Cyclin E1-positive PROC — a 2.1x separation from Cyclin E1-negative patients, presented at ESMO 2026 Oct 23. The single biggest gap in the prior bear case just got partially addressed.BD extracted 1 program update from this document → ZNTL pipeline
- Sep 2, 2026ReleaseZentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
- Aug 14, 20268-KCurrent report: other events
- Aug 14, 2026424B5Prospectus supplement (offering)
- Aug 13, 2026424B5Prospectus supplement (offering)
- Aug 6, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Aug 6, 202610-QQuarterly report
- Jun 18, 20268-KCurrent report: shareholder vote
- May 27, 2026DEFA14AProxy soliciting material
- May 27, 20268-KCurrent report: officer / director change
- May 21, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- May 12, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 12, 202610-QQuarterly report
- May 5, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 30, 2026DEFA14AProxy soliciting material
- Apr 30, 2026DEF 14AProxy statement
- Apr 17, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Apr 9, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Mar 26, 20268-KCurrent report: results of operations · EX-99.1
- Mar 26, 202610-KAnnual report
8 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Oct 27, 2026SCHEDULE 13G/A13G amendment
- Aug 19, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Jul 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 30, 2026ARSAnnual report to shareholders
- Mar 3, 2026SCHEDULE 13GPassive >5% holder (13G)